-
1.发明授权Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme 有权11-β-羟基类固醇脱氢酶1型酶抑制剂的使用方法公开(公告)号：US09133145B2
公开(公告)日：2015-09-15
申请号：US13782054
申请日：2013-03-01
Applicant: AbbVie Inc.
Inventor： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Steven X. Fung , Peer B. Jacobson , Lynne E. Rueter , Marina I. Strakhova , Jiahong Wang , James T. Link , Yixian Chen , Hwan-soo Jae , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Qi Shuai , Bryan K. Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
IPC: A61K31/496 , A61K31/55 , C07D295/155 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/42 , C07D213/72 , C07D231/12 , C07D239/42 , A61K31/5375 , C07D277/82 , C07D295/125 , C07D307/68 , C07D401/04 , C07D401/12 , C07D413/12 , C07D487/04 , C07D491/056
CPC classification number: C07D295/155 , A61K31/496 , A61K31/5375 , A61K31/55 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/42 , C07D213/72 , C07D231/12 , C07D239/42 , C07D277/82 , C07D295/125 , C07D307/68 , C07D401/04 , C07D401/12 , C07D413/12 , C07D487/04 , C07D491/056
Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
Abstract translation: 本发明涉及11-β-羟基类固醇脱氢酶1型酶的抑制剂及其在治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖，脂质障碍，代谢综合征，中枢神经系统疾病和疾病和病症中的用途 这与过量的糖皮质激素有关。
-
公开(公告)号：US20140336167A1
公开(公告)日：2014-11-13
申请号：US13891338
申请日：2013-05-10
Applicant: AbbVie Inc.
Inventor： Ramzi F. Sweis , Michael L. Curtin , Marina A. Pliushchev , Todd M. Hansen , Kenton Longenecker
IPC: C07D417/14 , C07D417/12
CPC classification number: A61K31/506 , A61K31/427 , A61K31/4439 , A61K31/496 , A61K31/497 , C07D417/12 , C07D417/14
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
Abstract translation: 公开了抑制NAMPT活性的化合物，含有该化合物的组合物和治疗其中NAMPT表达的疾病的方法。
-
公开(公告)号：US20170320880A1
公开(公告)日：2017-11-09
申请号：US15588398
申请日：2017-05-05
Applicant: AbbVie Inc.
Inventor： Michael R. Michaelides , Michael L. Curtin , Huan-Qiu Li , Marina A. Pliushchev , Ying Wang , Hongyu H. Zhao , Richard F. Clark , Alan S. Florjancic , Zhiqin Ji , Mariazel Torrent , Ramzi F. Sweis , Anil Vasudevan , Justin D. Dietrich
IPC: C07D487/04 , C07D417/14 , C07D413/10 , C07D405/04 , C07D403/14 , C07D403/12 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D471/04 , C07D207/14
CPC classification number: C07D487/04 , A61K31/40 , C07D207/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D413/10 , C07D417/14 , C07D471/04
Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号：US09187472B2
公开(公告)日：2015-11-17
申请号：US13891366
申请日：2013-05-10
Applicant: AbbVie Inc.
Inventor： Richard F. Clark , Bryan Sorensen , Augustine T. Osuma , Robin Frey , Kenton Longenecker , George Doherty , Michael L. Curtin , Michael R. Michaelides , Ramzi F. Sweis , Marina A. Pliushchev , Andy Judd , Todd M. Hansen , Howard R. Heyman
IPC: C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61K45/06 , A61K31/5377 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/55 , A61K31/407
CPC classification number: A61K31/437 , A61K31/407 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US09464072B2
公开(公告)日：2016-10-11
申请号：US14569203
申请日：2014-12-12
Applicant: AbbVie Inc.
Inventor： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Long , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC: A61K31/451 , A61K31/4523 , A61K31/55 , C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
CPC classification number: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
Abstract translation: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经变性，抑郁和精神分裂症，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
Patent Agency Ranking
公开(公告)号：US09334264B2
公开(公告)日：2016-05-10
申请号：US13891338
申请日：2013-05-10
Applicant: AbbVie Inc.
Inventor： Ramzi F. Sweis , Michael L. Curtin , Marina A. Pliushchev , Todd M. Hansen , Kenton Longenecker
IPC: C07D417/14 , C07D417/12
CPC classification number: A61K31/506 , A61K31/427 , A61K31/4439 , A61K31/496 , A61K31/497 , C07D417/12 , C07D417/14
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US20130303511A1
公开(公告)日：2013-11-14
申请号：US13891366
申请日：2013-05-10
Applicant: AbbVie Inc.
Inventor： Richard F. Clark , Bryan Sorensen , Augustine T. Osuma , Robin Frey , Kenton Longenecker , George Doherty , Michael L. Curtin , Michael R. Michaelides , Ramzi F. Sweis , Marina A. Pliushchev , Andy Judd , Todd M. Hansen , Howard R. Heyman
IPC: C07D471/04 , A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/437 , A61K31/5377
CPC classification number: A61K31/437 , A61K31/407 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US20130303508A1
公开(公告)日：2013-11-14
申请号：US13891349
申请日：2013-05-10
Applicant: AbbVie Inc.
Inventor： Richard F. Clark , Bryan Sorensen , Augustine T. Osuma , Robin Frey , Kenton Longenecker , George Doherty , Michael L. Curtin , Michael R. Michaelides , Ramzi F. Sweis , Marina A. Pliushchev , Andy Judd , Todd M. Hansen , Howard R. Heyman
IPC: C07D471/04 , A61K31/5377 , A61K45/06 , A61K31/496 , A61K31/55 , A61K31/4725 , A61K31/437 , A61K31/4545
CPC classification number: A61K31/437 , A61K31/407 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US20160193209A1
公开(公告)日：2016-07-07
申请号：US15068131
申请日：2016-03-11
Applicant: AbbVie Inc.
Inventor： Ramzi F. Sweis , Michael L. Curtin , Marina A. Pliushchev , Todd M. Hansen , Kenton Longenecker
IPC: A61K31/506 , A61K31/496 , A61K31/497 , A61K31/4439 , A61K31/427
CPC classification number: A61K31/506 , A61K31/427 , A61K31/4439 , A61K31/496 , A61K31/497 , C07D417/12 , C07D417/14
Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US20150274660A1
公开(公告)日：2015-10-01
申请号：US14229021
申请日：2014-03-28
Applicant: AbbVie Inc.
Inventor： Marina A. Pliushchev , Gary G. Chiang , William N. Pappano , Michael R. Michaelides , Ramzi F. Sweis
IPC: C07D209/40 , C07D403/12 , C07D209/96
CPC classification number: C07D209/40 , C07D209/96 , C07D403/12
Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.
Abstract translation: 本文描述了用于治疗受试者中的癌症，炎症或自身免疫性疾病或用于抑制组蛋白甲基转移酶G9a的化合物，药物组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.067 seconds)
